Fish oil and Body's own healing molecules could lift long COVID depression

NCT ID NCT07711444

Completed Symptom relief Sponsor: National Science and Technology Council, Taiwan Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests whether two dietary supplements—eicosapentaenoic acid (EPA), an omega-3 fatty acid, and specialized pro-resolving lipid mediators (SPMs)—can reduce depressive symptoms in adults with long COVID. Participants take either EPA, SPMs, or a placebo daily for 12 weeks. The goal is to see if these natural compounds can improve mood and mental health after a COVID-19 infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Eicosapentaenoic acid (omega-3 fatty acid) and Specialized Pro-Resolving Lipid Mediator (SPM)
What this could lead to: If effective, these supplements could offer a new, low-risk way to treat depression in long COVID patients.
What could go wrong: This is a small, early-stage trial, and results may not apply to everyone. Supplements can have side effects and may not outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 Depression long COVID-19 major depressive disorder post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 DEPRESSION - MAJOR DEPRESSIVE DISORDER

Contacts and locations

Show contact details

Locations

Mind-Body Interface Research Center (MBI Lab & Care)

Taichung, Taichung, 404, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.